Alaa A.A. Aljabali*, Hamid A. Bakshi, Saurabh Satija, Meenu Metha, Parteek Prasher, Raed M. Ennab, Dinesh K. Chellappan, Gaurav Gupta, Poonam Negi, Rohit Goyal, Ashish Sharma, Vijay Mishra, Harish Dureja, Kamal Dua and Murtaza M. Tambuwala Pages 323 - 353 ( 31 )
Background: The newly emerged coronavirus SARS-CoV-2, first reported in December 2019, has infected about five and a half million people globally and resulted in nearly 9063264 deaths until the 24th of June 2020. Nevertheless, the highly contagious virus has instigated an unimaginably rapid response from scientific and medical communities.
Objectives: Pioneering research on molecular mechanisms underlying the viral transmission, molecular pathogenicity, and potential treatments will be highlighted in this review. The development of antiviral drugs specific to SARS-CoV-2 is a complicated and tedious process. To accelerate scientific discoveries and advancement, researchers are consolidating available data from associated coronaviruses into a single pipeline, which can be readily made available to vaccine developers.
Methods: In order to find studies evaluating the COVID-19 virus epidemiology, repurposed drugs and potential vaccines, web searches and bibliographical bases have been used with keywords that matches the content of this review.
Results: The published results of SARS-CoV-2 structures and interactomics have been used to identify potential therapeutic candidates. We illustrate recent publications on SARS-CoV-2, concerning its molecular, epidemiological, and clinical characteristics, and focus on innovative diagnostics technologies in the production pipeline. This objective of this review is to enhance the comprehension of the unique characteristics of SARS-CoV-2 and strengthen future control measures.
Lay Summary: An innovative analysis is evaluating the nature of the COVID-19 pandemic. The aim is to increase knowledge of possible viral detection methods, which highlights several new technology limitations and advantages. We have assessed some drugs currently for patients (Lopinavir, Ritonavir, Anakinra and Interferon beta 1a), as the feasibility of COVID-19 specific antivirals is not presently known. The study explores the race toward vaccine development and highlights some significant trials and candidates in various clinical phases. This research addresses critical knowledge gaps by identifying repurposed drugs currently under clinical trials. Findings will be fed back rapidly to the researchers interested in COVID 19 and support the evidence and potential of possible therapeutics and small molecules with their mode of action.
COVID-19, epidemiology, pandemics, SARS-CoV-2, therapeutics repurposing, therapeutics, viruses.
Faculty of Pharmacy, Department of Pharmaceutics and Pharmaceutical Technology, Yarmouk University, Irbid 566, School of Pharmacy and Pharmaceutical Science, Ulster University, Coleraine, County Londonderry, Northern Ireland, School of Pharmaceutical Sciences, Lovely Professional University, Phagwara-144411, Punjab, School of Pharmaceutical Sciences, Lovely Professional University, Phagwara-144411, Punjab, Department of Chemistry, University of Petroleum & Energy Studies, Dehradun 248007, Department of Clinical sciences, Faculty of Medicine, Yarmouk University, Irbid 566, Department of Life Sciences, School of Pharmacy, International Medical University, Bukit Jalil, Kuala Lumpur 57000, School of Pharmacy, Suresh Gyan Vihar University, Jagatpura, Jaipur 302017, School of Pharmaceutical Sciences, Shoolini University of Biotechnology and Management Sciences, Solan, Neuropharmacology Laboratory, School of Pharmaceutical Sciences, Shoolini University, Solan 173 212, Himachal Pradesh, Neuropharmacology Laboratory, School of Pharmaceutical Sciences, Shoolini University, Solan 173 212, Himachal Pradesh, School of Pharmaceutical Sciences, Lovely Professional University, Phagwara-144411, Punjab, Department of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak 124001, School of Pharmaceutical Sciences, Shoolini University of Biotechnology and Management Sciences, Solan, School of Pharmacy and Pharmaceutical Science, Ulster University, Coleraine, County Londonderry, Northern Ireland